Impact of Body Mass Index on the One-Year Clinical Outcome of Patients Undergoing Multivessel Revascularization With Sirolimus-Eluting Stents (from the Arterial Revascularization Therapies Study Part II) † † Conflicts of interest: Magdaleen Pieters, Kristel Wittebols, and Hans-Peter Stoll are employees of Cordis Corporation. Joost Daemen received a consultancy fee for his scientific contribution

• Published in: The American journal of cardiology 2008-06, Vol.101 (11), p.1550-1559
• Main Authors: Khattab, Ahmed A., Daemen, Joost, Richardt, Gert, Rioux, Philippe, Amann, Franz-Wolfgang, Levy, Richard, Horvath, Ivan G., Teles, Rui C., Ordoubadi, Fath, Pieters, Magdaleen, Wittebols, Kristel, Stoll, Hans-Peter, Serruys, Patrick W.
• Format: Article
• Language: English
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2008.02.034

The differential safety and efficacy profiles of sirolimus-eluting stents when implanted in patients with multivessel coronary artery disease who have increased body mass indexes (BMIs) compared with those with normal BMIs are largely unknown. This study evaluated the impact of BMI on 1-year outcomes in patients with multivessel coronary artery disease treated with sirolimus-eluting stents as part of the Arterial Revascularization Therapies Study Part II (ARTS II). From February to November 2003, 607 patients were included at 45 centers; 176 patients had normal BMIs (30 kg/m 2). At 30 days, the cumulative incidence of the primary combined end point of death, myocardial infarction, cerebrovascular accident, and repeat revascularization (major adverse cardiac and cerebrovascular events) was 3.4% in the group with normal BMIs, 3.1% in overweight patients, and 2.8% in obese patients (p = 0.76). At 1 year, the cumulative incidence of major adverse cardiac and cerebrovascular events was 10.8%, 11.8%, and 7.0% in the normal BMI, overweight, and obese groups, respectively (p = 0.31). In conclusion, BMI had no impact on 1-year clinical outcomes in patients with multivessel coronary artery disease treated with sirolimus-eluting stents in ARTS II.